Skip to content

Clinical transformation study of non-invasive prenatal detection hemoglobin Bart hydrops fetalis via maternal plasma based on targeted capture sequencing of fetal free DNA combined with Bayesian model

Clinical transformation study of non-invasive prenatal detection hemoglobin Bart hydrops fetalis via maternal plasma based on targeted capture sequencing of fetal free DNA combined with Bayesian model

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122979
Enrollment
Unknown
Registered
2026-04-20
Start date
2024-10-26
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alpha-thalassemia

Interventions

Inspection Team:Non invasive detection of severe alpha thalassemia

Sponsors

Guangdong Women and Children Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Both parents are SEA thalassemia carriers; 2.Gestational age > 12 weeks; 3.No other indications for prenatal diagnosis; 4.Willing to provide informed consent and enroll in the study.

Exclusion criteria

Exclusion criteria: 1.Not both spouses are SEA thalassemia carriers, or refusal to enroll; 2.Inability to obtain adequate and valid samples for any reason; 3.Blood transfusion within six months for any reason; 4.Any other conditions deemed unsuitable for participation by the investigator.

Design outcomes

Primary

MeasureTime frame
positive concordance rate;Negative concordance rate;Kappa score;

Countries

China

Contacts

Public ContactAihua Yin

Guangdong Women and Children Hospital

yinaiwa@vip.126.com+86 138 2641 0392

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026